Marco Aurélio Oliveira

Marco Aurélio Oliveira

Auto-generated profile, based on publicly available information

Marco Aurélio Oliveira

Center Research Clinical, University of São Paulo, Bauru, Brazil

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Journal of the Korean Association of Oral and Maxillofacial Surgeons
Verified
Journal Article
Open access
PDF file
BMBrena Rodrigues Manzano
Brena Rodrigues Manzano
NSNatália Garcia Santaella
Natália Garcia Santaella
MOMarco Aurélio Oliveira
Marco Aurélio Oliveira
CRCássia Maria Fischer Rubira
Cássia Maria Fischer Rubira
PSPaulo Sérgio da Silva Santos
Paulo Sérgio da Silva Santos
Manzano BR, et al. J Korean Assoc Oral Maxillofac Surg. 2019 Feb;45(1):21-28. https://doi.org/10.5125/jkaoms.2019.45.1.21

1 June 2015 in Therapeutic Drug Monitoring
Verified
Journal Article
Closed access
TGThiago Gagliano-Jucá
Thiago Gagliano-Jucá
MCMaísa R. Castelli
Maísa R. Castelli
GMGustavo D. Mendes
Gustavo D. Mendes
AAAndré M. M. Arruda
André M. M. Arruda
LCLu Shi Chen
Lu Shi Chen
GNGilberto De Nucci
Gilberto De Nucci
Nanorap is a new nanotechnological formulation for topical anesthesia composed of lidocaine (2.5%) and prilocaine (2.5%). This study evaluated the pharmacokinetics of Nanorap. For the determination of lidocaine and prilocaine in human plasma, a new method using high-performance liquid chromatography coupled with tandem mass spectrometry was developed. Nanorap pharmacodynamic (PD) and its physical proprieties were also evaluated. Nanorap was administered by topical application of 2 g to healthy volunteers, and blood samples were collected for the pharmacokinetics analysis. The drugs were extracted from plasma by liquid–liquid extraction with ether/hexane (80/20, vol/vol). The chromatography separation was performed on a Genesis C18 analytical column 4 μm (100 × 2.1 mm i.d.) with a mobile phase of methanol/acetonitrile/water (40/30/30, for lidocaine, and 50/30/20, for prilocaine, vol/vol/vol) + 2 mM of ammonium acetate and ropivacaine as internal standard. The drugs were quantified using a mass spectrometer with an electrospray source in the electrospray ionization positive mode configured for multiple reaction monitoring. The PD of Nanorap was evaluated with the use of a visual analog scale. Nanorap was characterized by cryofracture. The chromatography run-time was 5.5 minutes for lidocaine and 3.3 minutes for prilocaine, and the lower limit of quantification was 0.05 ng/mL for both drugs. Mean Cmax was 6.62 and 1.72 ng/mL for lidocaine and prilocaine, respectively. Median Tmax was 6.5 hours for both drugs. Nanocapsules had a mean size of 88 nm and mean drug association of 92.5% and 89% for lidocaine and prilocaine, respectively. The PD study showed that Nanorap has a sufficient analgesic effect (>30% reduction in pain) after 10 minutes of application. A new simple, selective, and sensitive method for determination of lidocaine and prilocaine in human plasma was developed. Nanorap generated safe plasma levels of the drugs and satisfactory analgesic effect.

30 October 2020 in Journal of Oral Research
Verified
Journal Article
Open access
PDF file
ESEmanoele Paixão da Silva Silva
Emanoele Paixão da Silva Silva
RCRaquel D'Aquino Garcia Caminha
Raquel D'Aquino Garcia Caminha
MZMarcelo Junior Zanda
Marcelo Junior Zanda
PSPaulo Sérgio da Silva Santos
Paulo Sérgio da Silva Santos
Background: Oral mucositis (OM) is an inflammation of the oral mucosa due to cancer therapy that compromises the patient’s quality of life. Laser Doppler flowmetry (LDF) is a non-invasive method to monitor microvascular blood flow (BF) in real-time. Purpose: Develop a method to evaluate BF in the genian region cheek in patients undergoing chemotherapy by LDF and compare the degrees of OM and pain with evaluation of BF. Material and methods: Evaluation of OM was performed using the World Health Organization (WHO) and Oral Mucositis Assessment Scale (OMAS) scales and the visual analog scale for pain evaluation. For flowmetry analysis, a laser Doppler flowmeter (moorVMSTM™, 780 nm wavelength and VP3 probe), fixed by an acrylic resin support was used; VP3 probe was positioned on the genian region and the patient’s head was stabilized with a neck pillow for an accurate measurement. The Wilcoxon test was used to compare the flowmetry results at the studied times. The Pearson correlation coefficient was used to evaluate relationships between BF and the WHO, OMAS and visual analog scales. Results: Eleven patients of both sexes, aged between 30 and 78 years, with OM were included. An increase in cutaneous BF was observed at the initial times of OM, with progressive reduction during the chemotherapy cycle. There was a statistical difference (p<0.05) between time point T0 (first consultation) and time point T6 (last consultation). Conclusion: The method developed in this pilot study is effective, reliable, and reproducible, and allows the evaluation of BF dynamics in the genian region using LDF of patients undergoing chemotherapy at risk of developing OM.